Anticonvulsant and gabapentinoids pharmacotherapy in the multiple sclerosis prodrome: A population-based matched cohort study

IF 2.9 3区医学 Q2 CLINICAL NEUROLOGY Multiple sclerosis and related disorders Pub Date : 2024-11-16 DOI:10.1016/j.msard.2024.106167

Himali Bergeron-Vitez , Fardowsa LA Yusuf , Feng Zhu , Yinshan Zhao , Charity Evans , John D Fisk , Ruth Ann Marrie , John LK Kramer , Helen Tremlett

{"title":"Anticonvulsant and gabapentinoids pharmacotherapy in the multiple sclerosis prodrome: A population-based matched cohort study","authors":"Himali Bergeron-Vitez , Fardowsa LA Yusuf , Feng Zhu , Yinshan Zhao , Charity Evans , John D Fisk , Ruth Ann Marrie , John LK Kramer , Helen Tremlett","doi":"10.1016/j.msard.2024.106167","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Before disease onset, multiple sclerosis (MS) persons fill more prescriptions than controls, including for pain. However, knowledge regarding neuropathic pain-related medications is lacking</div></div><div><h3>Objective</h3><div>Compare odds of anticonvulsant/gabapentinoid prescriptions for 4,862 MS-cases versus 22,669 controls, pre-MS onset (defined as first demyelinating disease-related event).</div></div><div><h3>Methods</h3><div>Matched-cohort study using administrative data (1996–2013), comparing the odds of anticonvulsant/gabapentinoid prescriptions pre-MS onset using multivariable logistic regression.</div></div><div><h3>Results</h3><div>Versus controls, MS-cases were more likely to fill prescriptions for anticonvulsants (aOR[adjusted odds ratios] = 3.1,95 % confidence interval[CI]:2.8,3.4), gabapentinoids (aOR = 4.1,95 %CI:3.6,4.6), and gabapentinoids without anticonvulsants (aOR = 3.9,95 %CI:3.4,4.5).</div></div><div><h3>Conclusion</h3><div>MS-cases filled anticonvulsant and gabapentinoid prescriptions more than matched controls pre-MS onset.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"93 ","pages":"Article 106167"},"PeriodicalIF":2.9000,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multiple sclerosis and related disorders","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2211034824007430","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Before disease onset, multiple sclerosis (MS) persons fill more prescriptions than controls, including for pain. However, knowledge regarding neuropathic pain-related medications is lacking

Objective

Compare odds of anticonvulsant/gabapentinoid prescriptions for 4,862 MS-cases versus 22,669 controls, pre-MS onset (defined as first demyelinating disease-related event).

Methods

Matched-cohort study using administrative data (1996–2013), comparing the odds of anticonvulsant/gabapentinoid prescriptions pre-MS onset using multivariable logistic regression.

Results

Versus controls, MS-cases were more likely to fill prescriptions for anticonvulsants (aOR[adjusted odds ratios] = 3.1,95 % confidence interval[CI]:2.8,3.4), gabapentinoids (aOR = 4.1,95 %CI:3.6,4.6), and gabapentinoids without anticonvulsants (aOR = 3.9,95 %CI:3.4,4.5).

Conclusion

MS-cases filled anticonvulsant and gabapentinoid prescriptions more than matched controls pre-MS onset.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

Multiple sclerosis and related disorders CLINICAL NEUROLOGY-

CiteScore

5.80

自引率

20.00%

发文量

814

审稿时长

66 days

期刊介绍： Multiple Sclerosis is an area of ever expanding research and escalating publications. Multiple Sclerosis and Related Disorders is a wide ranging international journal supported by key researchers from all neuroscience domains that focus on MS and associated disease of the central nervous system. The primary aim of this new journal is the rapid publication of high quality original research in the field. Important secondary aims will be timely updates and editorials on important scientific and clinical care advances, controversies in the field, and invited opinion articles from current thought leaders on topical issues. One section of the journal will focus on teaching, written to enhance the practice of community and academic neurologists involved in the care of MS patients. Summaries of key articles written for a lay audience will be provided as an on-line resource. A team of four chief editors is supported by leading section editors who will commission and appraise original and review articles concerning: clinical neurology, neuroimaging, neuropathology, neuroepidemiology, therapeutics, genetics / transcriptomics, experimental models, neuroimmunology, biomarkers, neuropsychology, neurorehabilitation, measurement scales, teaching, neuroethics and lay communication.